M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals

Table 3 Non-invasive assessment data obtained at baseline and sustained virologic response 12 from patients stratified according to the fibrosis grade

Parameter					P value
Baseline (Total n = 80)	F0-1 (n = 29)	F2 (n = 20)	F3 (n = 5)	F4 (n = 26)
LSM (kPa)	5.9 ± 0.6	7.8 ± 0.5	10.8 ± 1.2	20.6 ± 7.7	< 0.001b
FIB-4 score	1.7 ± 1.4	1.4 ± 0.7	1.8 ± 0.4	2.3 ± 1.5	0.108
PAPAS index	2.1 ± 0.4	2.2 ± 0.6	2.3 ± 0.3	2.3 ± 0.5	0.303
Serum M2BPGi (ng/mL)	4.5 ± 2.2	5.3 ± 2.8	9.4 ± 4	14.5 ± 6.7	0.001b
SVR 12 (Total n = 80)	F0-1 (n = 35)	F2 (n = 23)	F3 (n = 6)	F4 (n = 16)
LSM (kPa)	5.8 ± 1.2	7.6 ± 0.6	9.9 ± 0.8	15 ± 2.3	< 0.001b
FIB-4 score	1.1 ± 0.5	1.5 ± 1	1.3 ± 0.6	1.6 ± 0.5	0.075
PAPAS index	2 ± 0.3	2.1 ± 0.3	2.1 ± 0.3	2.3 ± 0.3	0.069
Serum M2BPGi (ng/mL)	3.4 ± 1.6	4.9 ± 2.1	12.7 ± 5.1	13.3 ± 5.2	0.001b

^bP < 0.01. The values are expressed as mean ± SD. SVR: Sustained virologic response; LSM: Liver stiffness measurement; M2BPGi: Mac-2 binding protein glycosylation isomer.